Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more
Rekah Pharmaceutical Industry Ltd (REKA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.026x
Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) has a cash flow conversion efficiency ratio of 0.026x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA3.92 Million) by net assets (ILA150.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rekah Pharmaceutical Industry Ltd - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Rekah Pharmaceutical Industry Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Rekah Pharmaceutical Industry Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rekah Pharmaceutical Industry Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cavalry Capital Corp.
V:CVY-P
|
-0.184x |
|
AdvanceTC Limited
PINK:ATCLF
|
0.000x |
|
SNEP
BC:SNEP
|
N/A |
|
Rasna Therapeutics Inc
PINK:RASP
|
0.016x |
|
XTRACT RES PLC LS -0002
F:R9XN
|
N/A |
|
Norsk Solar AS
OL:NSOL
|
-0.911x |
|
Janus Electric Holdings Ltd
AU:JNS
|
0.000x |
|
FASTENAL (FAS.SG)
STU:FAS
|
0.083x |
Annual Cash Flow Conversion Efficiency for Rekah Pharmaceutical Industry Ltd (2004–2024)
The table below shows the annual cash flow conversion efficiency of Rekah Pharmaceutical Industry Ltd from 2004 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA161.98 Million | ILA26.54 Million | 0.164x | -10.07% |
| 2023-12-31 | ILA155.59 Million | ILA28.35 Million | 0.182x | -24.28% |
| 2022-12-31 | ILA162.08 Million | ILA39.00 Million | 0.241x | +96.73% |
| 2021-12-31 | ILA173.06 Million | ILA21.17 Million | 0.122x | +79.52% |
| 2020-12-31 | ILA165.59 Million | ILA11.28 Million | 0.068x | -68.81% |
| 2019-12-31 | ILA155.22 Million | ILA33.91 Million | 0.218x | +90.45% |
| 2018-12-31 | ILA150.66 Million | ILA17.28 Million | 0.115x | -30.28% |
| 2017-12-31 | ILA144.62 Million | ILA23.80 Million | 0.165x | -23.69% |
| 2016-12-31 | ILA105.86 Million | ILA22.82 Million | 0.216x | +359.22% |
| 2015-12-31 | ILA123.66 Million | ILA5.81 Million | 0.047x | +172.04% |
| 2014-12-31 | ILA77.06 Million | ILA1.33 Million | 0.017x | -88.28% |
| 2013-12-31 | ILA79.51 Million | ILA11.71 Million | 0.147x | -26.12% |
| 2012-12-31 | ILA71.17 Million | ILA14.18 Million | 0.199x | +88.75% |
| 2010-12-31 | ILA63.78 Million | ILA6.73 Million | 0.106x | -73.98% |
| 2009-12-31 | ILA64.15 Million | ILA26.03 Million | 0.406x | +261.86% |
| 2008-12-31 | ILA58.62 Million | ILA6.57 Million | 0.112x | -39.57% |
| 2007-12-31 | ILA67.10 Million | ILA12.45 Million | 0.186x | +155.46% |
| 2005-12-31 | ILA58.85 Million | ILA4.27 Million | 0.073x | -80.15% |
| 2004-12-31 | ILA48.86 Million | ILA17.87 Million | 0.366x | -- |